Vivozon Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
Vivozon Pharmaceutical Co., Ltd.'s Market Cap is ₩1952B. At end of 2025 it was ₩2336B. Ranked #825 of 2,410 in KR market (top 34%), #372 of 1,631 on KOSDAQ (top 23%), #93 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 40%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 195.21B KRW | KR#825/2,410 Sec#93/231 |
| Revenue | 50.34B KRW | KR#1,786/2,410 Sec#122/231 |
| Net Income | -32.83B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 163.53B KRW | KR#1,443/2,410 Sec#111/231 |
| Net Assets | 95.30B KRW | KR#1,451/2,410 Sec#116/231 |
| Employees | 394 | KR#619/2,410 Sec#53/231 |
| Value | ||
| P/B | 2.05x | KR#1,983/2,410 Sec#148/231 |
| P/S | 3.88x | KR#2,086/2,410 Sec#133/231 |
| FCF Yield | -4.24% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -34.44% | KR#2,208/2,410 Sec#185/231 |
| ROA | -20.07% | KR#2,234/2,410 Sec#175/231 |
| Op. Margin | -37.52% | KR#2,191/2,410 Sec#156/231 |
| Revenue Growth | -39.54% | KR#2,252/2,410 Sec#200/231 |
| Financial Health | ||
| Debt Ratio | 71.59% | KR#1,238/2,410 Sec#150/231 |
| Total Debt | 32.20B KRW | KR#1,188/2,410 Sec#87/231 |
| FCF | -8.28B KRW | KR#1,646/2,410 Sec#137/231 |
| Cash | 8.72B KRW | KR#1,765/2,410 Sec#157/231 |
| Current Ratio | 0.66x | KR#2,056/2,410 Sec#196/231 |
| Performance | ||
| 1Y Return | -33.40% | KR#1,582/2,410 Sec#128/231 |
| 1M Return | 8.61% | KR#135/2,410 Sec#9/231 |
| From 52W High | -50.00% | KR#1,233/2,410 Sec#98/231 |
| 1Y MDD | -62.52% | KR#1,582/2,410 Sec#127/231 |
| Trading | ||
| Volume | 187,164 shares | KR#356/2,410 Sec#34/231 |
| Trading Value | 588.6M KRW | KR#730/2,410 Sec#78/231 |
| Foreign Own. | 1.43% | KR#1,844/2,410 Sec#183/231 |
| Per Share | ||
| EPS | -541 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,570 KRW | KR#2,183/2,410 Sec#189/231 |
Company Info
VIVAZON Pharm, established in 2002 and listed on KOSDAQ in 2005, is a finished pharmaceutical product manufacturing and sales company. It possesses over 190 items, including cardiovascular drugs, dermatological external preparations, and antipyretic analgesics and anti-inflammatory drugs, engaging in ETC, OTC, CMO, OEM businesses, and overseas exports. The company's pharmaceutical research institute focuses on developing generics, combination drugs, formulation changes, and differentiated products using controlled-release technology. VIVAZON Pharm is headquartered in Hwaseong-si, Gyeonggi-do.